Spatially Resolved Transcriptomic Profiling of PRAME Oncogene Expression in Skin Cutaneous Melanoma: Elucidating Dermato-Oncology Therapy through Molecular Docking
- 20 September 2024
- journal article
- research article
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 23 (10) , 1289-1302
Abstract
Background: Skin cutaneous melanoma (SKCM) is a highly aggressive form of skin cancer characterized by rapid metastasis and poor prognosis. PRAME (Preferentially Expressed Antigen in Melanoma) is an oncogene overexpressed in various cancers, including melanoma, and is implicated in tumorigenesis and immune evasion. Understanding the spatial expression patterns of PRAME in SKCM can provide insights into the disease mechanism and therapeutic targets. Aim of the Study: This study aims to spatially resolve the transcriptomic profile of PRAME in SKCM and evaluate the therapeutic potential of selected dermato-oncology agents through molecular docking. Methods: Spatial transcriptomics was performed on SKCM tissue samples from 30 patients to map PRAME expression. Differential expression analysis and spatial clustering were conducted. Molecular docking using HDock assessed the binding affinities of PRAME with dermato-oncology agents: vemurafenib, dioxybenzone and octocrylene, as well as their conjugates (O-D: octocrylene-dioxybenzone, O-V: octocrylene-vemurafenib and D-V: dioxybenzone-vemurafenib). Chemsketch facilitated the creation of conjugates, and Pymol was used for visualization. Results: PRAME was significantly upregulated in SKCM tissues, with a mean expression level of 8.5 TPM compared to 1.2 TPM in normal tissues ([ ] < 0.001). HDock analysis revealed that dioxybenzone had a binding energy of –106.08 kcal/mol, octocrylene –107.04 kcal/mol, and vemurafenib –114.15 kcal/mol. The conjugates showed improved binding affinities: O-D had –142.93 kcal/mol, O-V had –152.69 kcal/mol and D-V had –184.53 kcal/mol, with D-V showing the most substantial binding affinity. Conclusion: Spatial transcriptomic profiling highlights PRAME as a key biomarker in SKCM. The molecular docking results indicate that D-V conjugates (dioxybenzone-vemurafenib) possess the highest binding affinity (–184.53 kcal/mol), suggesting a promising therapeutic potential for SKCM treatment. These findings support further investigation into D-V conjugates as targeted treatments for melanoma. Future Prospects: Future research should focus on in vivo validation of the identified therapeutic agents and exploring the role of PRAME in SKCM pathogenesis. Additionally, combining spatial transcriptomics with other omics data could enhance our understanding of the tumor microenvironment and lead to novel therapeutic approaches.Keywords
Funding Information
- Taif University, Saudi Arabia (TU-DSPP-2024-15)
This publication has 9 references indexed in Scilit:
- Investigating the anti-cancer compounds from Calliandra harrisii for precision medicine in pancreatic cancer via in-silico drug design and GC-MS analysisZeitschrift für Naturforschung C, 2024
- GC–MS profiling of Bacillus spp. metabolites with an in vitro biological activity assessment and computational analysis of their impact on epithelial glioblastoma cancer genesFrontiers in Chemistry, 2023
- Identification of a novel tumour microenvironment‐based prognostic biomarker in skin cutaneous melanomaJournal of Cellular and Molecular Medicine, 2021
- New Prognostic Biomarkers and Drug Targets for Skin Cutaneous Melanoma via Comprehensive Bioinformatic Analysis and ValidationFrontiers in Oncology, 2021
- An Insight into FDA Approved Antibody-Drug Conjugates for Cancer TherapyMolecules, 2021
- PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM)Journal of Immunotherapy, 2021
- Distinct alterations of CD68+CD163+ M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatmentJournal of Translational Medicine, 2018
- PRAME Is a Golgi-Targeted Protein That Associates with the Elongin BC Complex and Is Upregulated by Interferon-Gamma and Bacterial PAMPsPLOS ONE, 2013
- Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neckBritish Journal of Cancer, 1996